<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of endophthalmitis due to molds
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of endophthalmitis due to molds
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of endophthalmitis due to molds
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marlene L Durand, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer E Thorne, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carol A Kauffman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Keri K Hall, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 13, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H634314692">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endophthalmitis due to molds is uncommon in temperate climates but is common in tropical regions such as India.
         <em>
          Fusarium
         </em>
         and
         <em>
          Aspergillus
         </em>
         spp account for most cases of mold endophthalmitis. Mold endophthalmitis often results in loss of vision.
        </p>
        <p>
         The treatment of endophthalmitis due to molds will be reviewed here. The epidemiology, clinical features, and diagnosis of fungal endophthalmitis are discussed elsewhere. The treatment of endophthalmitis caused by
         <em>
          Candida
         </em>
         and bacterial species are also presented separately.
         <em>
          Fusarium
         </em>
         keratitis is also discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/16953.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2446.html" rel="external">
          "Treatment of endogenous endophthalmitis and chorioretinitis due to Candida species"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16220.html" rel="external">
          "Treatment of exogenous endophthalmitis due to Candida species"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3418.html" rel="external">
          "Bacterial endophthalmitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15674.html" rel="external">
          "Treatment and prevention of Fusarium infection", section on 'Keratitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H198244885">
         <span class="h1">
          DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The term "endophthalmitis" means infection within the eye involving the vitreous and/or aqueous (
         <a class="graphic graphic_figure graphicRef57690" href="/z/d/graphic/57690.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         <strong>
          Endogenous endophthalmitis
         </strong>
         results from bacterial or fungal seeding of the eye via the bloodstream. In most cases of endogenous mold endophthalmitis, the highly vascular choroid is seeded first, and the infection typically progresses from the "back" of the eye (posterior segment) anteriorly.
        </p>
        <p>
         <strong>
          Exogenous endophthalmitis
         </strong>
         means the infection was introduced from the "outside," for example, following eye surgery or trauma or extension of fungal infection of the cornea (termed "fungal keratitis" or "keratomycosis"). In exogenous endophthalmitis, the aqueous is typically infected first and, in some cases, the vitreous is not involved.
        </p>
        <p class="headingAnchor" id="H634314713">
         <span class="h1">
          TREATMENT MODALITIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of mold endophthalmitis typically involves a combination of vitrectomy, intravitreal and/or intracameral (into the anterior chamber) injection of an antifungal agent, removal of foreign materials (eg, intraocular lens), and systemic antifungal therapy [
         <a href="#rid1">
          1-4
         </a>
         ]. Corneal transplantation is indicated in some cases of mold keratitis (corneal infection) that have extended to the aqueous [
         <a href="#rid5">
          5
         </a>
         ]. No controlled trials of treatment regimens for mold endophthalmitis have been performed given its rarity. The evidence regarding the treatment of mold endophthalmitis comes from case reports and case series. Even with therapy, there is a high rate of loss of useful vision, but it appears that the prognosis is improving with the availability of
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         . (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H365246849">
         <span class="h2">
          Vitrectomy and removal of foreign bodies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical removal of the vitreous, or vitrectomy, is nearly always necessary in mold endophthalmitis [
         <a href="#rid2">
          2,4-7
         </a>
         ]. Vitrectomy entails the use of a vitrector, an instrument inserted into the vitreous cavity that simultaneously cuts and aspirates some of the approximately 4 mL of gel-like vitreous into a canister (
         <a class="graphic graphic_figure graphicRef59512" href="/z/d/graphic/59512.html" rel="external">
          figure 2
         </a>
         ). During this process, a separate cannula infuses balanced salt solution into the vitreous cavity to maintain intraocular pressure. By the end of the case, the canister contains dilute vitreous "washings" (eg, 50 to 100 mL). Vitrectomy decreases the burden of fungi quickly by debriding the vitreous [
         <a href="#rid8">
          8
         </a>
         ]. Samples are obtained during vitrectomy for microbiologic studies, and intravitreal antibiotics are injected at the end of the case. A vitrectomy, which is typically performed with local anesthesia with sedation, may be difficult if there is so much inflammation that the retina surgeon cannot see the retina. In patients too ill for eye surgery, a needle aspiration of the vitreous (for stains and cultures) followed by an intravitreal antibiotic injection should be performed. If the aqueous is primarily involved, then needle aspiration of aqueous plus intracameral antibiotic injection should be performed.
        </p>
        <p>
         If only the aqueous is involved, as may occur in some cases of keratomycosis, then a vitrectomy may not be necessary. Even in such cases, intravitreal injection of
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         or
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         is often given in addition to injection into the aqueous (intracameral injection) due to concern for occult extension of fungal infection into the vitreous. Intravitreal and intracameral injections are discussed below. (See
         <a class="local">
          'Intravitreal antifungal therapy'
         </a>
         below and
         <a class="local">
          'Intracameral antifungal therapy'
         </a>
         below.)
        </p>
        <p>
         Successful treatment of mold endophthalmitis also requires removal of any foreign material (eg, an intraocular lens placed during cataract surgery or a foreign body introduced by penetrating eye trauma). Leaving any such foreign material in place may allow persistent infection despite antifungal therapy and nearly always leads to relapse of infection. Leaving an intraocular lens in place in postcataract fungal endophthalmitis is a risk factor for poor visual outcome [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H61418791">
         <span class="h2">
          Corneal transplantation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Corneal transplantation may be indicated in cases of keratomycosis due to molds in which the infection has extended into the aqueous. This is particularly true in corneas with extensive involvement, corneal melting, impending perforation, and/or poor response to treatment [
         <a href="#rid10">
          10
         </a>
         ]. The treatment of
         <em>
          Fusarium
         </em>
         keratitis is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/15674.html" rel="external">
          "Treatment and prevention of Fusarium infection", section on 'Keratitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H278655734">
         <span class="h2">
          Intravitreal antifungal therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intravitreal injection of either
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         or
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         is necessary for nearly all cases of mold endophthalmitis to ensure the rapid achievement of high levels of an antifungal drug inside the eye. No studies have compared the efficacy of intravitreal amphotericin B with intravitreal voriconazole.
        </p>
        <p>
         Intravitreal
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         has been used for many years; the usual dose is 5 or 10 mcg in 0.1 mL sterile water [
         <a href="#rid11">
          11
         </a>
         ]. Intravitreal
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         has been used successfully in a number of cases and appears to have less toxicity than amphotericin B [
         <a href="#rid1">
          1,12,13
         </a>
         ]. The usual dose of intravitreal voriconazole is 100 mcg in 0.1 mL sterile water [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         High doses of intravitreal
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         are toxic to the retina, but an intravitreal injection of 5 or 10 mcg (in 0.1 mL sterile water) appears to be safe and may be repeated several days later if evidence of intraocular infection persists on serial examinations. Patients have received cumulative intravitreal doses of 30 mcg amphotericin B deoxycholate without apparent retinal toxicity [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Based on animal studies and case series, intravitreal
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         also appears to be safe. In vitro toxicity studies of human retinal pigment epithelium cells and primary human ocular nerve head astrocytes, a concentration of voriconazole of 25 mcg/mL vitreous appears to be safe [
         <a href="#rid13">
          13
         </a>
         ]. In a study of rats, a dose of up to 25 mcg per mL vitreous was found to be safe based on electroretinography and histopathology findings [
         <a href="#rid15">
          15
         </a>
         ]. This dose corresponds to an injection of 100 mcg into the adult human vitreous, which has a volume of approximately 4 mL. A dose of 50 to 100 mcg of voriconazole in 0.1 mL sterile water has been used in patients without apparent toxicity [
         <a href="#rid8">
          8,12,13,16-20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H278655727">
         <span class="h2">
          Intracameral antifungal therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In rare cases in which the aqueous humor is significantly involved, such as in early postcataract surgery mold endophthalmitis or early endophthalmitis due to keratomycosis, an intracameral (into the anterior chamber) injection of
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         or
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         should be given. Intracameral amphotericin B deoxycholate has been used for many years to treat exogenous fungal endophthalmitis [
         <a href="#rid21">
          21
         </a>
         ]. More recently, it has been used to treat refractory cases of keratomycosis, including some with extension into the aqueous [
         <a href="#rid22">
          22,23
         </a>
         ]. Increasingly, intracameral and intravitreal voriconazole have been used in place of amphotericin B. The rationale for intracameral injections is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/16220.html" rel="external">
          "Treatment of exogenous endophthalmitis due to Candida species", section on 'Intraocular therapy'
         </a>
         .)
        </p>
        <p>
         The usual dose of
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         for intracameral injection is 5 mcg in 0.1 mL sterile water. Transient increase in eye pain (lasting up to 12 hours) and anterior chamber inflammation, including hypopyon, have occurred following intracameral amphotericin B injections [
         <a href="#rid22">
          22,24
         </a>
         ].
        </p>
        <p>
         The optimal dose of intracameral
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         has not been well established, but 50 to 100 mcg in 0.1 mL sterile water is usually used. Intracameral voriconazole has been used without apparent toxicity. In one in vitro study of cultured human ocular cells, a concentration of 250 mcg/mL of voriconazole for 30 days did not appear to cause toxicity either to corneal or endothelial trabecular meshwork cells [
         <a href="#rid25">
          25
         </a>
         ]. In another in vitro study, voriconazole concentrations up to 50 mcg/mL did not decrease the viability of corneal endothelial cells, but concentrations ≥100 mcg/mL led to a reduction in cell viability [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         Several studies have reported effective use of intracameral
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         at doses ranging from 12.5 mcg to 100 mcg in 0.1 mL sterile water [
         <a href="#rid10">
          10,12,16
         </a>
         ]. Intracameral doses of 100 mcg of voriconazole have been used repeatedly in some eyes without any apparent toxicity [
         <a href="#rid10">
          10
         </a>
         ], but we prefer a dose of 50 mcg due to the limited experience with intracameral voriconazole and because this dose produces sufficiently high concentrations in the aqueous.
        </p>
        <p>
         Intracameral
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         has been shown to have a half-life of only 22 minutes in an experimental rabbit model [
         <a href="#rid27">
          27
         </a>
         ], so topical voriconazole 1% solution can be used to prolong the drug level in the aqueous. Topical voriconazole given frequently produces high levels of voriconazole in the aqueous [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1311134809">
         <span class="h2">
          Topical antifungal therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neither
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         1% solution nor
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         0.15% solution are commercially available as eye drops, but both have been widely used for treatment of keratomycosis. Their role in the treatment of mold endophthalmitis has not been defined, but topical voriconazole may be indicated as adjunctive therapy in some cases. Topical voriconazole penetrates the intact human cornea, and repeated application may produce therapeutic levels in the aqueous. Two studies of patients with intact corneas reported that repeated doses of topical voriconazole 1% produced therapeutic aqueous levels [
         <a href="#rid29">
          29,30
         </a>
         ].
        </p>
        <p>
         For topical
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         , no human studies are available. However, studies in rabbits show that topical amphotericin B does not penetrate an intact cornea but does penetrate a corneal debrided of epithelium [
         <a href="#rid31">
          31
         </a>
         ]. It is therefore possible that in patients with keratomycosis-associated endophthalmitis primarily involving the aqueous, amphotericin B eye drops may have some benefit as adjunctive therapy in cases due to voriconazole-resistant fungi.
        </p>
        <p class="headingAnchor" id="H365247006">
         <span class="h2">
          Systemic antifungal therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic antifungal therapy is indicated for endogenous mold endophthalmitis, and the choice of systemic therapy should be based on optimal treatment for invasive fungal infection. The treatment of invasive fungal infections is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">
          "Treatment and prevention of invasive aspergillosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15674.html" rel="external">
          "Treatment and prevention of Fusarium infection"
         </a>
         .)
        </p>
        <p>
         In exogenous mold endophthalmitis, vitrectomy and intraocular injections of antifungal agents (
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         or
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         ) alone may suffice, but the addition of systemic voriconazole is almost always indicated unless the fungus is known to be resistant to azoles. Systemic amphotericin B is not usually given in exogenous endophthalmitis because the significant toxicity of this therapy is usually not justified by the uncertain benefit. In experimental studies, systemic amphotericin B deoxycholate achieves minimal intraocular levels in uninflamed rabbit eyes, although higher levels are achieved in inflamed rabbit eyes when multiple-dose regimens are used over seven days [
         <a href="#rid32">
          32
         </a>
         ]. Liposomal amphotericin may achieve higher vitreous concentrations than other lipid formulations of amphotericin B or amphotericin B deoxycholate [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          Voriconazole
         </a>
         is the treatment of choice for systemic
         <em>
          Aspergillus
         </em>
         infections; it is also active against
         <em>
          Fusarium
         </em>
         and these two fungi account for the majority of mold endophthalmitis cases. Voriconazole achieves vitreous levels with oral administration that are nearly 40 percent of plasma levels [
         <a href="#rid33">
          33
         </a>
         ]. In addition to endophthalmitis caused by
         <em>
          Aspergillus
         </em>
         spp and
         <em>
          Fusarium
         </em>
         spp, voriconazole has also been used to treat endophthalmitis due to
         <em>
          Paecilomyces lilacinus
         </em>
         ,
         <em>
          Scedosporium apiospermum
         </em>
         , and
         <em>
          Lecythophora mutabilis
         </em>
         [
         <a href="#rid18">
          18,34-36
         </a>
         ]. Oral voriconazole, in combination with vitrectomy and intravitreal
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         , was used successfully to treat a case of exogenous
         <em>
          Fusarium
         </em>
         endophthalmitis and a case of
         <em>
          Aspergillus
         </em>
         endophthalmitis [
         <a href="#rid37">
          37
         </a>
         ]. The patient with
         <em>
          Aspergillus
         </em>
         endophthalmitis also received intravenous (IV)
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         ; it is not clear whether caspofungin contributed to the success of therapy in this case.
        </p>
        <p>
         It is important to measure serum concentrations of
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         four to seven days after initiating systemic therapy to ensure that adequate concentrations have been achieved to allow success and to avoid high levels that have been associated with adverse events. Although debate remains over the optimal target concentration, available data suggest a therapeutic range of greater than 1 mg/L and less than 5.5 mg/L. In patients with concentrations that are too high or too low, the serum concentration should be rechecked four to five days after adjusting the dose. Once appropriate levels have been achieved, it is not necessary to recheck them unless there is a change in clinical status or concern for toxicity (eg, transaminitis) or drug-drug interactions. (See
         <a class="medical medical_review" href="/z/d/html/495.html" rel="external">
          "Pharmacology of azoles", section on 'Serum drug concentration monitoring'
         </a>
         .)
        </p>
        <p>
         The intraocular concentration of
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         has not been studied in animal models and it may not achieve adequate concentrations using the oral suspension. The oral suspension of posaconazole has been used with success as salvage therapy in a few complicated cases of
         <em>
          Fusarium
         </em>
         keratitis-related endophthalmitis and endophthalmitis that had not responded to therapy with either
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         or amphotericin B [
         <a href="#rid38">
          38-40
         </a>
         ]. In one patient successfully treated with both topical and the oral suspension of posaconazole for refractory
         <em>
          Fusarium
         </em>
         keratitis-related endophthalmitis, the vitreous concentration one week after keratoplasty was approximately 20 percent of the plasma concentration (0.25 mcg/mL in vitreous, 1.2 mcg/mL in plasma), and the aqueous concentration three months later was 0.9 mcg/mL (with plasma level of 1.6 mcg/mL) [
         <a href="#rid39">
          39
         </a>
         ]. It is not clear whether the newer delayed-release posaconazole tablet that is much simpler for patients to take and that results in higher serum concentrations will prove useful for ocular infections.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">
          Isavuconazole
         </a>
         has been shown to be noninferior to
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         in treating invasive aspergillosis and is also approved for the treatment of mucormycosis [
         <a href="#rid41">
          41
         </a>
         ]. There is limited information about penetration of isavuconazole into the eye. A study in rats demonstrated good levels of the drug following oral administration in most tissues, including the brain and uveal tract [
         <a href="#rid42">
          42
         </a>
         ]. However, studies measuring intraocular levels in humans have not been published. Isavuconazole treatment of mold endophthalmitis has not been reported, but a single case of endogenous
         <em>
          Candida dubliniensis
         </em>
         endophthalmitis successfully treated with isavuconazole after failing other systemic treatments (
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         , amphotericin) has been reported [
         <a href="#rid43">
          43
         </a>
         ]. At this time this agent cannot be recommended for treatment of mold endophthalmitis.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          Fluconazole
         </a>
         is
         <strong>
          not
         </strong>
         recommended because of its poor activity against molds.
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          Itraconazole
         </a>
         is not used due to poor penetration into the vitreous. The echinocandins are active against
         <em>
          Aspergillus
         </em>
         spp but not
         <em>
          Fusarium
         </em>
         spp or other molds. There are few data on the ability of the echinocandins to cross the blood-eye barrier, but adequate concentrations would be unlikely given the large size of these molecules and the high degree of protein binding. In experiments in rabbits of systemically administered
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         and
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         , these agents were undetectable in the vitreous [
         <a href="#rid44">
          44,45
         </a>
         ]. However, micafungin produced concentrations in the retina-choroid that were comparable with plasma concentrations [
         <a href="#rid45">
          45
         </a>
         ]. An individual case report showed success with caspofungin for a case of postcataract surgery
         <em>
          Acremonium
         </em>
         endophthalmitis that had failed amphotericin B treatment [
         <a href="#rid46">
          46
         </a>
         ]. Caspofungin plus
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         was successful in a case of
         <em>
          Aspergillus
         </em>
         endophthalmitis [
         <a href="#rid37">
          37
         </a>
         ], but it is not clear that the addition of caspofungin added to the effectiveness of voriconazole. Echinocandins alone are
         <strong>
          not
         </strong>
         recommended for the treatment of mold endophthalmitis given the lack of efficacy data, their limited spectrum of activity against molds, and the concern that vitreous concentrations are low.
        </p>
        <p class="headingAnchor" id="H634314720">
         <span class="h1">
          APPROACH TO TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to treatment depends on several factors, including whether the infection is exogenous or endogenous and the infecting agent. With endogenous infections, the treatment depends on whether the patient has a localized ocular infection (versus a systemic infection) at the time of presentation. Most immunocompromised patients have a concurrent systemic fungal infection. In contrast, most patients who have endogenous endophthalmitis as the result of injection drug use developed endophthalmitis as a result of transient fungemia and may not have any other sites of fungal infection. Treatment requires a combination of modalities, which may include vitrectomy, aspiration of the aqueous, removal of any foreign body (eg, intraocular lens), corneal transplantation, injection of an antifungal agent into the vitreous and/or aqueous, topical and systemic antifungal therapy. Specific treatment recommendations are provided below.
        </p>
        <p class="headingAnchor" id="H66569008">
         <span class="h2">
          Exogenous mold endophthalmitis
         </span>
        </p>
        <p class="headingAnchor" id="H66568942">
         <span class="h3">
          Anterior segment involvement only
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with endophthalmitis involving only the anterior segment of the eye (
         <a class="graphic graphic_figure graphicRef57690" href="/z/d/graphic/57690.html" rel="external">
          figure 1
         </a>
         ), such as from extension of mold keratomycosis, we suggest the following treatment approach:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aspirate the aqueous for stains and cultures. (See
         <a class="medical medical_review" href="/z/d/html/16953.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Surgically remove any foreign body, such as an intraocular lens (eg, placed during prior cataract surgery).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inject either
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         (50 mcg in 0.1 mL sterile water) or
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         (5 mcg in 0.1 mL sterile water) into the aqueous. Voriconazole is preferred for molds such as
         <em>
          Aspergillus
         </em>
         or
         <em>
          Fusarium
         </em>
         that are typically susceptible to voriconazole.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Corneal transplantation may be indicated in cases of keratomycosis due to molds in which the infection has extended into the aqueous. The management of
         <em>
          Fusarium
         </em>
         keratitis is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/15674.html" rel="external">
          "Treatment and prevention of Fusarium infection", section on 'Keratitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administer topical antifungal drops (
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         1% or
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         0.15% in sterile water) frequently (eg, hourly) in cases of keratomycosis-related endophthalmitis. Topical voriconazole is preferred for susceptible fungi since it penetrates the cornea well and achieves good concentrations in the aqueous humor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administer systemic
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         (6 mg/kg IV every 12 hours for two doses, then 4 mg/kg IV every 12 hours for patients with severe disease), except in those rare cases due to voriconazole-resistant molds. Oral therapy, using 200 mg twice daily on an empty stomach, can be used following an initial response to the IV formulation. In less severe cases, oral voriconazole can be used as initial therapy; the oral loading dose is 400 mg twice daily for two doses, followed by 200 mg twice daily. Some patients may require higher doses than 200 mg twice daily to achieve adequate serum concentrations because of significant interpatient variability in voriconazole serum levels. As noted above, it is important to measure serum concentrations of voriconazole four to seven days after initiating systemic therapy to ensure that adequate concentrations have been achieved to allow success and to avoid high levels that have been associated with adverse events. (See
         <a class="local">
          'Systemic antifungal therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/495.html" rel="external">
          "Pharmacology of azoles", section on 'Serum drug concentration monitoring'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Even if there is no apparent vitreous involvement, consider injecting
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         (100 mcg in 0.1 mL sterile water) or
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         (5 or 10 mcg in 0.1 mL sterile water) into the vitreous since there may be occult vitreous infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Repeat injection of
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         or
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         into the aqueous and/or vitreous if no improvement has occurred. Injections may be repeated more than once, but voriconazole is preferred for such repeated injections because intracameral amphotericin B deoxycholate may cause anterior segment inflammation. (See
         <a class="local">
          'Intracameral antifungal therapy'
         </a>
         above and
         <a class="local">
          'Vitreous involvement'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H66568950">
         <span class="h3">
          Vitreous involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with exogenous endophthalmitis involving the vitreous, we suggest the following treatment approach:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perform a vitrectomy to decrease the fungal burden and to obtain a sample for stains and cultures (see
         <a class="medical medical_review" href="/z/d/html/16953.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis", section on 'Diagnosis'
         </a>
         ). In the rare case in which the retina specialist feels that they cannot safely perform a vitrectomy or in patients too ill for eye surgery, a vitreous aspirate should be obtained for stains and cultures, although the diagnostic yield is lower than with vitrectomy. Surgically remove any foreign body, such as an intraocular lens (eg, placed during prior cataract surgery).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administer an intravitreal injection of
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         (5 or 10 mcg in 0.1 mL sterile water) or
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         (100 mcg in 0.1 mL sterile water). A repeat injection may be indicated after several days if there has been no response to therapy. We favor the first injection to be amphotericin B deoxycholate if the identity of the fungus is unknown, but we prefer voriconazole for subsequent injections if the fungus is susceptible. More than one repeat intravitreal injection may be given.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If there is involvement of the aqueous, administer an intracameral injection of
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         (50 mcg in 0.1 mL sterile water) or
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         (5 mcg in 0.1 mL sterile water).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administer systemic
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         (6 mg/kg IV every 12 hours for two doses, then 4 mg/kg IV every 12 hours). The IV formulation is recommended for at least the initial few days for patients who have an acute presentation. Oral therapy at a dose of 200 mg twice daily taken on an empty stomach can be used following an initial response to the IV formulation. Some patients may require higher doses than 200 mg twice daily to achieve adequate serum concentrations because of significant interpatient variability in voriconazole serum levels. As noted above, it is important to measure serum concentrations of voriconazole four to seven days after initiating systemic therapy to ensure that adequate concentrations have been achieved to allow success and to avoid high levels that have been associated with adverse events (see
         <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">
          "Treatment and prevention of invasive aspergillosis", section on 'Voriconazole'
         </a>
         ). If the fungus is resistant to voriconazole, or has recurred despite maximal therapy (eg, repeated intravitreal injections of
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         or voriconazole, vitrectomy, removal of all foreign material such as an intraocular lens, removal of an infected cornea if present), then systemic liposomal amphotericin could be used, but these cases are rare.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H79284393">
         <span class="h2">
          Endogenous endophthalmitis
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perform a vitrectomy to decrease the fungal burden and to obtain a sample for stains and cultures (see
         <a class="medical medical_review" href="/z/d/html/16953.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis", section on 'Diagnosis'
         </a>
         ). In the rare case in which the retina specialist feels that they cannot safely perform a vitrectomy, or in patients too ill for eye surgery, a vitreous aspirate should be obtained for stains and cultures, although the diagnostic yield is lower than with vitrectomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Surgically remove any foreign material (eg, intraocular lens).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administer intravitreal
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         (5 or 10 mcg in 0.1 mL sterile water) or intravitreal
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         (100 mcg in 0.1 mL sterile water). Repeat the intravitreal injection of voriconazole or amphotericin B after several days if no improvement has occurred. We recommend that the first injection be amphotericin B deoxycholate if the identity of the fungus is unknown, but we recommend voriconazole for subsequent injections if the fungus is one likely to be susceptible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administer systemic antifungal therapy, optimized to the most likely fungal pathogen involved. This may be either a systemic amphotericin B formulation or
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         . The usual dosing of these agents is as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">
          Liposomal amphotericin B
         </a>
         – 5 mg/kg IV once daily; we favor this formulation of amphotericin B because it achieves higher concentrations in the central nervous system compared with other lipid formulations or
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         ; the blood-eye barrier is similar to the blood-brain barrier. (See
         <a class="medical medical_review" href="/z/d/html/2453.html" rel="external">
          "Candida infections of the central nervous system", section on 'Antifungal therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          Voriconazole
         </a>
         – 6 mg/kg IV every 12 hours for two doses, then 4 mg/kg IV every 12 hours. The IV formulation is recommended for at least the initial few days. Oral therapy at a dose of 200 mg twice daily on an empty stomach can be used following an initial response to the IV formulation. Higher doses may be required in obese patients. As noted above, it is important to measure serum concentrations of voriconazole four to seven days after initiating systemic therapy to ensure that adequate concentrations have been achieved to allow success and to avoid high levels that have been associated with adverse events. (See
         <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">
          "Treatment and prevention of invasive aspergillosis", section on 'Voriconazole'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The treatment of invasive aspergillosis and fusariosis is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">
          "Treatment and prevention of invasive aspergillosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15674.html" rel="external">
          "Treatment and prevention of Fusarium infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H165207918">
         <span class="h2">
          Duration of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The duration of systemic antifungal therapy for mold endophthalmitis depends upon the improvement of lesions as determined by serial ophthalmic examinations but also whether the infection was exogenous or endogenous. If exogenous, therapy is usually continued for at least one month (and sometimes several months) after resolution of all signs of active intraocular infection. For endogenous endophthalmitis, the duration of therapy is determined by the type, extent, and response to therapy of the systemic fungal infection being treated; treatment usually extends for several months.
        </p>
        <p class="headingAnchor" id="H234846856">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The visual prognosis in mold endophthalmitis has historically been poor, with at least two-thirds of eyes losing useful vision [
         <a href="#rid21">
          21,47,48
         </a>
         ]. A large series of fungal endophthalmitis from India reported poor outcomes in the majority of patients with mold endophthalmitis, although systemic
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         was not part of the treatment regimen [
         <a href="#rid7">
          7
         </a>
         ].Outcomes appear to be better when systemic voriconazole is included in the treatment regimen (for susceptible isolates) and for patients diagnosed early and treated aggressively. Exogenous and endogenous mold endophthalmitis cases have achieved very good visual outcomes with aggressive therapy [
         <a href="#rid49">
          49,50
         </a>
         ]. A series from Texas reported excellent outcomes of five cases of mold endophthalmitis due to
         <em>
          Fusarium
         </em>
         ,
         <em>
          Scedosporium
         </em>
         , or
         <em>
          Glomerella
         </em>
         species
         <em>
          ,
         </em>
         with aggressive treatment, including systemic and intravitreal voriconazole [
         <a href="#rid51">
          51
         </a>
         ]. The infection cleared in all eyes and four patients recovered excellent vision (20/20 in three, 20/50 in one); the remaining patient had poor baseline vision due to glaucoma and nearly recovered that vision.
        </p>
        <p class="headingAnchor" id="H346086707">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         <strong>
          –
         </strong>
         Endophthalmitis due to molds often results in loss of vision. It is rarely diagnosed in temperate climates, but it is common in tropical regions.
         <em>
          Fusarium
         </em>
         and
         <em>
          Aspergillus
         </em>
         spp account for most cases of mold endophthalmitis. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         <strong>
          –
         </strong>
         A sample of vitreous (and/or aqueous, if it is involved) should be obtained for stains and cultures prior to antifungal treatment. (See
         <a class="local">
          'Approach to treatment'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/16953.html" rel="external">
          "Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         <strong>
          –
         </strong>
         A combination of interventions are necessary including surgical removal of any foreign bodies, vitrectomy in most cases, and intraocular and systemic antifungal therapy. We use the following approach (see
         <a class="local">
          'Approach to treatment'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Surgery and intraocular antifungal therapy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Removal of foreign bodies
         </strong>
         <strong>
          –
         </strong>
         All foreign bodies should be surgically removed. (See
         <a class="local">
          'Approach to treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Exogenous endophthalmitis involving the anterior segment only
         </strong>
         <strong>
          –
         </strong>
         For these patients, we recommend intracameral (into the aqueous) injection of either
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         (50 mcg in 0.1 mL sterile water) or
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         (5 mcg in 0.1 mL sterile water) (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ). In such patients, we also recommend frequent administration (eg, hourly) of topical antifungal drops (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ). We prefer voriconazole (1% topical solution) rather than amphotericin B deoxycholate drops if the fungus is susceptible to voriconazole. Intravitreal voriconazole injection should also be considered even if there is no apparent vitreous involvement, since this involvement may be occult. (See
         <a class="local">
          'Anterior segment involvement only'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         When exogenous mold endophthalmitis involving the aqueous arises from extension of keratomycosis, a corneal transplant may also be indicated to reduce the fungal burden and control the infection. The management of
         <em>
          Fusarium
         </em>
         keratitis is discussed in detail separately. (See
         <a class="local">
          'Anterior segment involvement only'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/15674.html" rel="external">
          "Treatment and prevention of Fusarium infection", section on 'Keratitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Exogenous or endogenous endophthalmitis involving the vitreous
         </strong>
         <strong>
          –
         </strong>
         For these individuals
         <strong>
          ,
         </strong>
         we recommend a vitrectomy to debride the vitreous in nearly all cases (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ). A sample of vitreous should be sent for stains and cultures. An intravitreal injection of either
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         or
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         (voriconazole if the fungus is susceptible) should be administered at the end of the procedure. If the ophthalmologist considers a vitrectomy too risky, or if the patient is too ill for eye surgery, a needle aspiration of the vitreous (for stains and cultures) followed by injection of either amphotericin B deoxycholate or voriconazole should be performed. The usual dose of intravitreal amphotericin B deoxycholate is 5 or 10 mcg in 0.1 mL sterile water, and the usual dose of intravitreal voriconazole is 100 mcg in 0.1 mL sterile water. (See
         <a class="local">
          'Vitreous involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         If the eye has not improved, we favor a repeat intravitreal injection of either
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         (for susceptible fungi) or
         <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">
          amphotericin B deoxycholate
         </a>
         after several days. Intravitreal voriconazole (100 mcg in 0.1 mL sterile water) is preferred over intravitreal amphotericin B deoxycholate (5 or 10 mcg in 0.1 mL sterile water) for fungi susceptible to voriconazole. Intravitreal injections may be repeated more than once for eyes that fail to improve despite maximal therapy (ie, vitrectomy, removal of foreign material, intravitreal and systemic antifungal therapy). (See
         <a class="local">
          'Vitreous involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Systemic antifungal therapy
         </strong>
         <strong>
          –
         </strong>
         We suggest systemic antifungals, depending on the source of endophthalmitis and the susceptibility of the mold to antifungal agents:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Exogenous endophthalmitis
         </strong>
         <strong>
          –
         </strong>
         We recommend administering systemic
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         for molds that are found to be susceptible to this agent (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ). For the rare isolate that is resistant to voriconazole and when the infection progresses despite maximal surgical and intraocular therapy, we consider using intravenous
         <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">
          liposomal amphotericin B
         </a>
         . (See
         <a class="local">
          'Exogenous mold endophthalmitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Endogenous endophthalmitis
         </strong>
         <strong>
          –
         </strong>
         These individuals all require systemic antifungal therapy with either
         <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">
          liposomal amphotericin B
         </a>
         or
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         , depending on the susceptibility of the mold. (See
         <a class="local">
          'Endogenous endophthalmitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2808805530">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Kieren A Marr, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis 2011; 52:648.
          </a>
         </li>
         <li class="breakAll">
          Patel AV, Young LH. Endogenous endophthalmitis. In: Endophthalmitis, Durand ML, Miller JW, Young LH (Eds), Springer International Publishing, Switzerland 2016. p.171.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durand ML. Bacterial and Fungal Endophthalmitis. Clin Microbiol Rev 2017; 30:597.
          </a>
         </li>
         <li class="breakAll">
          Durand ML. Endophthalmitis. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th ed, Mandell GL, Bennett JE, Dolin R (Eds), Elsevier, Philadelphia 2019.
         </li>
         <li class="breakAll">
          Kauffman CA. Exogenous fungal endophthalmitis. In: Endophthalmitis, Durand ML, Miller JW, Young LH (Eds), Springer International Publishing, Switzerland 2016. p.185.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chakrabarti A, Shivaprakash MR, Singh R, et al. Fungal endophthalmitis: fourteen years' experience from a center in India. Retina 2008; 28:1400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Das T, Agarwal M, Anand AR, et al. Fungal Endophthalmitis: Analysis of 730 Consecutive Eyes from 7 Tertiary Eye Care Centers in India. Ophthalmol Retina 2022; 6:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riddell Iv J, McNeil SA, Johnson TM, et al. Endogenous Aspergillus endophthalmitis: report of 3 cases and review of the literature. Medicine (Baltimore) 2002; 81:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Güngel H, Eren MH, Pınarcı EY, et al. An outbreak of Fusarium solani endophthalmitis after cataract surgery in an eye training and research hospital in Istanbul. Mycoses 2011; 54:e767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen YC, Wang CY, Tsai HY, Lee HN. Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis. Am J Ophthalmol 2010; 149:916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 63:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin RC, Sanduja N, Hariprasad SM. Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral voriconazole. J Ocul Pharmacol Ther 2008; 24:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kernt M, Neubauer AS, De Kaspar HM, Kampik A. Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis. Retina 2009; 29:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tabbara KF, al Jabarti AL. Hospital construction-associated outbreak of ocular aspergillosis after cataract surgery. Ophthalmology 1998; 105:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gao H, Pennesi ME, Shah K, et al. Intravitreal voriconazole: an electroretinographic and histopathologic study. Arch Ophthalmol 2004; 122:1687.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wykoff CC, Flynn HW Jr, Miller D, et al. Exogenous fungal endophthalmitis: microbiology and clinical outcomes. Ophthalmology 2008; 115:1501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sen P, Gopal L, Sen PR. Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series. Retina 2006; 26:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer M, Kramer MR, Blau H, et al. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis. Ophthalmology 2006; 113:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vila Arteaga J, Suriano MM, Stirbu O. Intravitreal voriconazole for the treatment of Aspergillus chorioretinitis. Int Ophthalmol 2011; 31:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhuang H, Ding X, Zhang T, et al. Vitrectomy combined with intravitreal antifungal therapy for posttraumatic fungal endophthalmitis in eastern China. BMC Ophthalmol 2020; 20:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pflugfelder SC, Flynn HW Jr, Zwickey TA, et al. Exogenous fungal endophthalmitis. Ophthalmology 1988; 95:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yilmaz S, Ture M, Maden A. Efficacy of intracameral amphotericin B injection in the management of refractory keratomycosis and endophthalmitis. Cornea 2007; 26:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon KC, Jeong IY, Im SK, et al. Therapeutic effect of intracameral amphotericin B injection in the treatment of fungal keratitis. Cornea 2007; 26:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuriakose T, Kothari M, Paul P, et al. Intracameral amphotericin B injection in the management of deep keratomycosis. Cornea 2002; 21:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kernt M, Kampik A. Intracameral voriconazole: in vitro safety for human ocular cells. Toxicology 2009; 258:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han SB, Shin YJ, Hyon JY, Wee WR. Cytotoxicity of voriconazole on cultured human corneal endothelial cells. Antimicrob Agents Chemother 2011; 55:4519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shen YC, Wang MY, Wang CY, et al. Pharmacokinetics of intracameral voriconazole injection. Antimicrob Agents Chemother 2009; 53:2156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vemulakonda GA, Hariprasad SM, Mieler WF, et al. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch Ophthalmol 2008; 126:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Senthilkumari S, Lalitha P, Prajna NV, et al. Single and multidose ocular kinetics and stability analysis of extemporaneous formulation of topical voriconazole in humans. Curr Eye Res 2010; 35:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neoh CF, Leung L, Chan E, et al. Open-Label Study of Absorption and Clearance of 1% Voriconazole Eye Drops. Antimicrob Agents Chemother 2016; 60:6896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qu L, Li L, Xie H. Corneal and aqueous humor concentrations of amphotericin B using three different routes of administration in a rabbit model. Ophthalmic Res 2010; 43:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldblum D, Rohrer K, Frueh BE, et al. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother 2002; 46:3719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004; 122:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garbino J, Ondrusova A, Baglivo E, et al. Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole. Scand J Infect Dis 2002; 34:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figueroa MS, Fortun J, Clement A, De Arévalo BF. Endogenous endophthalmitis caused by Scedosporium apiospermum treated with voriconazole. Retina 2004; 24:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott IU, Cruz-Villegas V, Flynn HW Jr, Miller D. Delayed-onset, bleb-associated endophthalmitis caused by Lecythophora mutabilis. Am J Ophthalmol 2004; 137:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Durand ML, Kim IK, D'Amico DJ, et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol 2005; 140:552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tu EY, McCartney DL, Beatty RF, et al. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol 2007; 143:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sponsel WE, Graybill JR, Nevarez HL, Dang D. Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol 2002; 86:829.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spriet I, Delaere L, Lagrou K, et al. Intraocular penetration of voriconazole and caspofungin in a patient with fungal endophthalmitis. J Antimicrob Chemother 2009; 64:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miceli MH, Kauffman CA. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. Clin Infect Dis 2015; 61:1558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmitt-Hoffmann AH, Kato K, Townsend R, et al. Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats. Antimicrob Agents Chemother 2017; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sng ECY, Tan AL, Zhou PY, et al. Candida Endophthalmitis Treated Successfully With Isavuconazole: A Case Report. Open Forum Infect Dis 2021; 8:ofab516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldblum D, Fausch K, Frueh BE, et al. Ocular penetration of caspofungin in a rabbit uveitis model. Graefes Arch Clin Exp Ophthalmol 2007; 245:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki T, Uno T, Chen G, Ohashi Y. Ocular distribution of intravenously administered micafungin in rabbits. J Infect Chemother 2008; 14:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornely OA, Schmitz K, Aisenbrey S. The first echinocandin: caspofungin. Mycoses 2002; 45 Suppl 3:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Essman TF, Flynn HW Jr, Smiddy WE, et al. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 1997; 28:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dursun D, Fernandez V, Miller D, Alfonso EC. Advanced fusarium keratitis progressing to endophthalmitis. Cornea 2003; 22:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young LH, Bazari H, Durand ML, Branda JA. Case records of the Massachusetts General Hospital. Case 33-2010. A 22-year-old woman with blurred vision and renal failure. N Engl J Med 2010; 363:1749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mithal K, Pathengay A, Bawdekar A, et al. Filamentous fungal endophthalmitis: results of combination therapy with intravitreal amphotericin B and voriconazole. Clin Ophthalmol 2015; 9:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bui DK, Carvounis PE. Favorable Outcomes of Filamentous Fungal Endophthalmitis Following Aggressive Management. J Ocul Pharmacol Ther 2016; 32:623.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16205 Version 29.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21239843" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21239843" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28356323" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Bacterial and Fungal Endophthalmitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28356323" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Bacterial and Fungal Endophthalmitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28356323" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Bacterial and Fungal Endophthalmitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19009680" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Fungal endophthalmitis: fourteen years' experience from a center in India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34547530" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Fungal Endophthalmitis: Analysis of 730 Consecutive Eyes from 7 Tertiary Eye Care Centers in India.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12169886" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Endogenous Aspergillus endophthalmitis: report of 3 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21627695" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : An outbreak of Fusarium solani endophthalmitis after cataract surgery in an eye training and research hospital in Istanbul.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20434131" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27365388" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18321199" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral voriconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18997637" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Intravitreal voriconazole: in vitro safety-profile for fungal endophthalmitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9499785" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hospital construction-associated outbreak of ocular aspergillosis after cataract surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15534131" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Intravitreal voriconazole: an electroretinographic and histopathologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18486220" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Exogenous fungal endophthalmitis: microbiology and clinical outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17031296" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16713628" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21769537" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Intravitreal voriconazole for the treatment of Aspergillus chorioretinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33143689" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Vitrectomy combined with intravitreal antifungal therapy for posttraumatic fungal endophthalmitis in eastern China.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3257818" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Exogenous fungal endophthalmitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17457185" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Efficacy of intracameral amphotericin B injection in the management of refractory keratomycosis and endophthalmitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17667615" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Therapeutic effect of intracameral amphotericin B injection in the treatment of fungal keratitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12352080" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Intracameral amphotericin B injection in the management of deep keratomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19428927" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Intracameral voriconazole: in vitro safety for human ocular cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21768517" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Cytotoxicity of voriconazole on cultured human corneal endothelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19258273" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Pharmacokinetics of intracameral voriconazole injection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18195213" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20958183" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Single and multidose ocular kinetics and stability analysis of extemporaneous formulation of topical voriconazole in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27550348" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Open-Label Study of Absorption and Clearance of 1% Voriconazole Eye Drops.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19887881" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Corneal and aqueous humor concentrations of amphotericin B using three different routes of administration in a rabbit model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12435667" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14718293" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12374371" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15097903" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Endogenous endophthalmitis caused by Scedosporium apiospermum treated with voriconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15013895" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Delayed-onset, bleb-associated endophthalmitis caused by Lecythophora mutabilis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16139017" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17258521" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12084760" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19684077" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Intraocular penetration of voriconazole and caspofungin in a patient with fungal endophthalmitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26179012" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28971866" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34909437" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Candida Endophthalmitis Treated Successfully With Isavuconazole: A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17120004" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Ocular penetration of caspofungin in a rabbit uveitis model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18574655" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Ocular distribution of intravenously administered micafungin in rabbits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12690973" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The first echinocandin: caspofungin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9076791" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12792470" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Advanced fusarium keratitis progressing to endophthalmitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20979476" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Case records of the Massachusetts General Hospital. Case 33-2010. A 22-year-old woman with blurred vision and renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25926714" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Filamentous fungal endophthalmitis: results of combination therapy with intravitreal amphotericin B and voriconazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27447804" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Favorable Outcomes of Filamentous Fungal Endophthalmitis Following Aggressive Management.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
